Spyre Therapeutics Inc. annual operating income for fiscal TTM was -$202 million, an increase of 3.8% from -$210 million in fiscal 2025. All figures are reported results from public filings — no estimates or projections.
| Operating Income (annual) | TTM → 2026-03-31 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (EBIT) | ($202M) | ($210M) | ($209M) | ($242M) | ($85M) | ($66M) | ($81M) | ($80M) | ($45M) | ($28M) | ($22M) | ($11M) | ($9M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Operating Income (quarterly) | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Income (EBIT) | — | ($46M) | ($57M) | ($57M) | ($42M) | ($54M) | ($61M) | ($55M) | ($44M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
More SYRE metrics: Revenue · Gross Profit · Net Income · EPS · EBITDA · Free Cash Flow · Shares Outstanding
All SYRE financial statements → Interactive SYRE charts →
About TickerBase · Data methodology & sources · Privacy · Terms